Sign in
CompletedNo phase

Emergence Agitation Between Dexmedetomidine and Sevoflurane Anesthesia

Key facts

Who runs it
Pelita Harapan University
Where
Indonesia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
121 people enrolled
Started
31 Jul 2024
Ended
31 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidine
  • Sevoflurane
Record updated
28 May 2025

Who can take part

Age
3 months to 10 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with weight ranging 5 kg - 25 kg
  • Patients with American Society of Anesthesiologist (ASA) Physical Status Classification 1 and 2

Who cannot take part

  • Patients with any acquired congenital syndrome
  • Patients who are actively taking anti-seizure medications and/or has been diagnosed with epilepsy
  • Patients with functional and structural abnormalities of the heart, including arrythmias
  • Patients with liver disease

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Emergence agitation is commonly encountered after receiving inhalation anesthesia. This distressing phenomenon carries risks that are harmful to patients, caregivers and medical personnel. Using total intravenous Dexmedetomidine, the investigators seek to reduce agitation and provide gentle emergence from anesthesia.

The 2 groups in the trial

  • Inhalation SevofluraneExisting treatment, for comparison

    Participants in this group will receive inhalation anesthesia Sevoflurane at 2-3 Vol% as their sole anesthetic maintenance agent throughout the surgical procedure.

    Treatment: Sevoflurane

  • Total Intravenous DexmedetomidineTreatment being tested

    Participants in this group will receive Total Intravenous Dexmedetomidine as their sole anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour will be given throughout the surgical procedure.

    Treatment: Dexmedetomidine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Emergence Agitation in Pediatrics After Dexmedetomidine vs. Sevoflurane Anesthesia: a Randomized Controlled Trial
Record updated
28 May 2025